CG Oncology Stock (NASDAQ:CGON)

Forecast Revenue Ownership Financials Chart

Previous Close

$44.29

52W Range

$14.80 - $45.56

50D Avg

$35.84

200D Avg

$28.43

Market Cap

$3.33B

Avg Vol (3M)

$909.33K

Beta

1.32

Div Yield

-

CGON Company Profile

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

113

IPO Date

-

Website

CGON Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Jun 25	Mar 25
Operating Segments	$52.00K	$52.00K

Fiscal year ends in Dec 24 | Currency in USD

CGON Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	$204.00K	$191.00K
Operating Income	$-114.67M	$-55.45M	$-35.25M
Net Income	$-88.04M	$-48.61M	$-35.44M
EBITDA	$-114.67M	$-55.43M	$-35.23M
Basic EPS	$-1.41	$-15.65	$-0.53
Diluted EPS	$-1.41	$-15.65	$-0.53

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
QURE	uniQure N.V.
AAPG	Ascentage Pharma Group International
TARS	Tarsus Pharmaceuticals, Inc.
SLNO	Soleno Therapeutics, Inc.
XENE	Xenon Pharmaceuticals Inc.
ZLAB	Zai Lab Limited
LEGN	Legend Biotech Corporation
CNTA	Centessa Pharmaceuticals plc
SRRK	Scholar Rock Holding Corporation
APGE	Apogee Therapeutics, Inc.